Nineteen relapsing remitting ( RR ) MS patients , randomly assigned to undergo either NTZ ( n = 10 ) or IFN B 1B ( n = 9 ) treatment , who had previously received NTZ for at least 12 months with disease stability and fearing or at risk for PML were included .